Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Dow
Moodys
AstraZeneca
Boehringer Ingelheim
Medtronic

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Litigation Details for GENENTECH, INC. v. CELLTRION, INC. (D.N.J. 2018)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

GENENTECH, INC. v. CELLTRION, INC. (D.N.J. 2018)

Docket   Start Trial Date Filed 2018-01-12
Court District Court, D. New Jersey Date Terminated 2018-11-01
Cause 15:1126 Patent Infringement Assigned To Renee Marie Bumb
Jury Demand Plaintiff Referred To Karen M. Williams
Parties BIOGEN, INC.; CELLTRION HEALTHCARE CO., LTD.; CELLTRION, INC.; CITY OF HOPE; GENENTECH, INC.; HOFFMANN-LA ROCHE INC.; TEVA PHARMACEUTICALS INTERNATIONAL GMBH; TEVA PHARMACEUTICALS USA, INC.
Patents 7,485,704; 7,807,799; 7,820,161; 7,976,838; 8,206,711; 8,329,172; 8,545,843; 8,557,244; 8,821,873; 9,296,821; 9,504,744
Attorneys CHRISTINE INTROMASSO GANNON; KEITH J. MILLER; LIZA M. WALSH; MICHAEL JAMES GESUALDO; WILLIAM T. WALSH , JR
Link to Docket External link to docket
Biologic Drugs cited in GENENTECH, INC. v. CELLTRION, INC.

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for GENENTECH, INC. v. CELLTRION, INC. (D.N.J. 2018)

Date Filed Document No. Description Snippet Link To Document
2018-07-05 46 Amended Complaint • U.S. Patent No. 7,485,704 86. U.S. Patent No. 7,485,704 (“the ’704 patent”) is entitled…DECLARATORY JUDGMENT OF INFRINGEMENT OF U.S. PATENT NO. 7,485,704) 157. Plaintiffs re-allege… COUNT 24 (INFRINGEMENT OF U.S. PATENT NO. 7,485,704 UNDER 35 U.S.C. § 271(E)(2)) …• U.S. Patent No. 6,489,447 78. U.S. Patent No. 6,489,447 (“the ’447 patent”) is entitled…• U.S. Patent No. 6,610,516 80. U.S. Patent No. 6,610,516 (“the ’516 patent”) is entitled External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
AstraZeneca
Moodys
Dow
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.